CD200R1 and neoplasm: CD200 is also broadly expressed in other solid tumors, such as pancreatic ductal adenocarcinoma, lung cancer, ovarian cancer, renal cell carcinoma, CNS malignancies and head and neck squamous carcinomas (HNSCC), where its interaction with CD200R(1) promotes immune suppression in tumor microenvironment.